Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab re-exposure safety study in multiple sclerosis
ACTRN12605000769684Phase 4Not yet recruiting
- Sponsor
- Biogen
- Start
- Mar 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of natalizumab in multiple sclerosis (MS), sponsored by Biogen. Planned start Mar 2006; status: not yet recruiting.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12605000769684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000769684.